[1]
Gami AS, Olson EJ, Shen WK, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol 2013; 62(7): 610-6.
[2]
Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation 2012; 125(4): 620-37.
[3]
Ilkhanoff L, Goldberger JJ. Out-of-hospital cardiac arrest. Circulation 2012; 126: 793-6.
[4]
Deo R, Norby FL, Katz R, et al. Development and validation of a sudden cardiac death prediction model for the general population. Circulation 2016; 134(11): 806-16.
[5]
Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large US community. J Am Coll Cardiol 2004; 44(6): 1268-75.
[6]
Sorensen C. Recent trends in survival from out-of-hospital cardiac arrest in the United States. J Emerg Med 2015; 48(3): 399-400.
[7]
Behere SP, Weindling SN. Inherited arrhythmias: The cardiac channelopathies. Ann Pediatr Cardiol 2015; 8(3): 210.
[8]
Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: Proposed diagnostic criteria. J Am Coll Cardiol 2011; 57(7): 802-12.
[9]
Kim JB, Kim SJ, Kang SY, Yi JW, Kim SM. The large-conductance calcium-activated potassium channel holds the key to the conundrum of familial hypokalemic periodic paralysis. Korean J Pediatr 2014; 57(10): 445-50.
[10]
Amin AS, Asghari-Roodsari A, Tan HL. Cardiac sodium channelopathies. Pflugers Arch 2010; 460(2): 223-37.
[11]
Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome. Circulation 2002; 106(19): 2514-9.
[12]
Kim JB. Channelopathies. Korean J Pediatr 2014; 57(1): 1-18.
[13]
Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008; 121(1): 66-71.
[14]
Ambrosi A, Sonesson SE, Wahren-Herlenius M. Molecular mechanisms of congenital heart block. Exp Cell Res 2014; 325(1): 2-9.
[15]
Lazzerini PE, Capecchi PL, Guideri F, et al. Autoantibody-mediated cardiac arrhythmias: Mechanisms and clinical implications. Basic Res Cardiol 2008; 103(1): 1-11.
[16]
Rehsia NS, Dhalla NS. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol 2010; 15(4): e86.
[17]
Lazzerini PE, Capecchi PL, Laghi-Pasini F, Boutjdir M. Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias. Nat Rev Cardiol 2017; 14(9): 521-35.
[18]
Bornholz B, Roggenbuck D, Jahns R, Boege F. Diagnostic and therapeutic aspects of β 1-adrenergic receptor autoantibodies in human heart disease. Autoimmun Rev 2014; 13(9): 954-62.
[19]
Zuo L, Du Y, Ma J, et al. Pro-arrhythmic action of autoantibodies against the second extracellular loop of β 1-adrenoceptor and its underlying molecular mechanisms. Int J Cardiol 2015; 198: 251-8.
[20]
Zhu WZ, Wang SQ, Chakir K, et al. Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A–independent activation of Ca2+/calmodulin kinase II. J Clin Invest 2003; 111(5): 617.
[21]
Dandel M, Wallukat G, Englert A, Hetzer R. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atheroscler Suppl 2013; 14(1): 203-11.
[22]
Patel PA, Hernandez AF. Targeting anti‐beta‐1‐adrenergic receptor antibodies for dilated cardiomyopathy. Eur J Heart Fail 2013; 15(7): 724-9.
[23]
Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human β 1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999; 99(5): 649-54.
[24]
Störk S, Boivin V, Horf R, et al. Stimulating autoantibodies directed against the cardiac β 1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006; 152(4): 697-704.
[25]
Chiale PA, Ferrari I, Mahler E, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001; 103(13): 1765-71.
[26]
Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of beta 1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37(2): 418-24.
[27]
Pei J, Li N, Chen J, et al. The predictive values of beta1‐adrenergic and M2 muscarinic receptor autoantibodies for sudden cardiac death in patients with chronic heart failure. Eur J Heart Fail 2012; 14(8): 887-94.
[28]
Xiao H, Wang M, Du Y, et al. Arrhythmogenic autoantibodies against calcium channel lead to sudden death in idiopathic dilated cardiomyopathy. Eur J Heart Fail 2011; 13(3): 264-70.
[29]
Yu H, Pei J, Liu X, et al. Calcium channel autoantibodies predicted sudden cardiac death and all-cause mortality in patients with ischemic and nonischemic chronic heart failure. Dis Markers 2014; 2014: 796075.
[30]
Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: Possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 40(6): 1153-9.
[31]
Lazzerini P, Capecchi P, Laghi‐Pasini F. Anti‐Ro/SSA antibodies and cardiac arrhythmias in the adult: Facts and hypotheses. Scand J Immunol 2010; 72(3): 213-22.
[32]
Lazzerini PE, Capecchi PL, Acampa M, et al. Arrhythmogenic effects of anti-Ro/SSA antibodies on the adult heart: More than expected? Autoimmun Rev 2009; 9(1): 40-4.
[33]
Karnabi E, Boutjdir M. Role of calcium channels in congenital heart block. Scand J Immunol 2010; 72(3): 226-34.
[34]
Fabris F, Yue Y, Qu Y, et al. Induction of autoimmune response to the extracellular loop of the HERG channel pore induces QTc prolongation in guinea‐pigs. J Physiol 2016; 594(21): 6175-87.
[35]
Lazzerini PE, Yue Y, Srivastava U, et al. Arrhythmogenicity of anti-Ro/SSA antibodies in patients with torsades de pointes. Circ Arrhythm Electrophysiol 2016; 9(4): e003419.
[36]
Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
[37]
Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101(25): 2883-8.
[38]
Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50(11): 3444-9.
[39]
Schirmer M, Vallejo AN, Weyand CM, Goronzy JJ. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients. J Immunol 1998; 161(2): 1018-25.
[40]
Lazzerini PE, Yue Y, Srivastava U, et al. Arrhythmogenicity of anti-Ro/SSA antibodies in patients with torsades de pointes. Circ Arrhythm Electrophysiol 2016; 9(4): e003419.
[41]
Liautaud S, Khan AJ, Nalamasu SR, Tan IJ, Onwuanyi AE. Variable atrioventricular block in systemic lupus erythematosus. Clin Rheumatol 2005; 24(2): 162-5.
[42]
Abu-Shakra M, Urowitz M, Gladman D, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 1995; 22(7): 1265-70.
[43]
Godeau P, Guillevin L, Fechner J, Bletry O, Herreman G, Eds. Disorders of conduction in lupus erythematosus: Frequency and incidence
in a group of 112 patients (author's transl). Annales de
medecine interne 1981.
[44]
Xie SK, Feng SF, Fu H. Long term follow‐up of patients with systemic lupus erythematosus. J Dermatol 1998; 25(6): 367-73.
[45]
Champion HC. The heart in scleroderma. Rheumatic diseases clinics of North America 2008; 34(1): 181-viii.
[46]
Logar D, Kveder T, Rozman B, Dobovisek J. Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 1990; 49(8): 627-9.
[47]
Teixeira RA, Borba EF, Bonfá E, Martinelli Filho M. Eventos arrítmicos no lúpus eritematoso sistêmico. Revista Brasileira de Reumatologia 2010; 50: 81-9.